A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

BACKGROUND AND PURPOSE: The aggregation of α-synuclein is connected to the pathology of Parkinson's disease and prolyl oligopeptidase (PREP) accelerates the aggregation of α-synuclein in vitro. The aim of this study was to investigate the effects of a PREP inhibitor, KYP-2047, on α-synuclein ag...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Myöhänen, TT, Hannula, MJ, Van Elzen, R, Gerard, M, Van Der Veken, P, García-Horsman, JA, Baekelandt, V, Männistö, PT, Lambeir, AM
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2012
Pynciau:
Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3417432/
https://ncbi.nlm.nih.gov/pubmed/22233220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.01846.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg